导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 7.46% | 988/4773 |
| 近一周 | -4.66% | 5256/5467 |
| 近一月 | -3.81% | 1377/5421 |
| 近一季 | -6.50% | 2056/5238 |
| 近半年 | -8.35% | 3562/4931 |
| 近一年 | 20.88% | 399/4400 |
| 近两年 | 71.80% | 973/2954 |
| 近三年 | 54.03% | 504/2253 |
| 成立以来 | 80.48% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
10.30% 64/4961 |
-1.24% 3342/5312 |
- - |
- - |
| 2025 | 38.78% 858/4813 |
-0.36% 2216/3635 |
2.76% 1380/4076 |
24.01% 1498/4524 |
9.30% 198/4813 |
| 2024 | 8.74% 1521/3463 |
7.85% 217/2808 |
-1.17% 962/3014 |
9.83% 2664/3129 |
-7.11% 2730/3463 |
| 2023 | -0.48% 456/2656 |
5.13% 824/2280 |
-5.63% 1509/2385 |
3.38% 187/2515 |
-2.97% 563/2655 |
| 2022 | -7.30% 142/2207 |
0.62% 111/1919 |
5.79% 824/2016 |
-8.25% 184/2113 |
-5.07% 1916/2208 |
| 2021 | 38.65% 41/1822 |
3.38% 180/1255 |
9.28% 569/1330 |
31.30% 12/1466 |
-6.52% 1539/1822 |
| 2020 | 38.05% 369/1250 |
-11.99% 867/1028 |
8.25% 827/1067 |
20.93% 46/1164 |
19.83% 68/1184 |
| 2019 | 23.81% 624/1092 |
20.11% 613/754 |
-2.20% 346/804 |
-4.37% 769/850 |
10.22% 154/918 |
| 2018 | -29.86% 458/834 |
- - |
- - |
- - |
-16.03% 622/691 |
| 2017 | 17.92% 214/714 |
- - |
- - |
- - |
- - |
| 2016 | -7.37% 215/605 |
- - |
- - |
- - |
- - |
| 2015 | 1.88% 242/575 |
- - |
- - |
- - |
- - |
| 2014 | 26.29% 177/237 |
- - |
- - |
- - |
- - |
| 2013 | -33.33% 179/186 |
- - |
- - |
- - |
- - |
| 2012 | 4.50% 84/140 |
- - |
- - |
- - |
- - |
| 2011 | -33.13% 98/102 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 国联安上证商品ETF联接A VS. 长安沪深300非周期A(740101) |